Recent

% | $
Quotes you view appear here for quick access.

POLYMEDIX CMN STK Message Board

mulletman99 3 posts  |  Last Activity: Aug 2, 2016 9:55 PM Member since: Feb 1, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Test

    by joncon63 Jul 27, 2016 9:12 AM
    mulletman99 mulletman99 Aug 2, 2016 9:55 PM Flag

    Guess so

  • mulletman99 by mulletman99 Jun 27, 2016 10:51 PM Flag

    1st I want to say thanks to Onebarkmill for the detailed summary.

    Known coming milestones(based on dates given in CC):
    - CardioPET clinical development report finished - ~2-3 weeks (early to mid July)
    - Complete chemistry validation and open enrollment for BFPET P2 trial - "early Q3" (July?)
    - Present CardioPET P2 comparative imaging data at ASNC - late Q3 (Sept 23)
    - Present CardioPET P2 safety data at EANM in early Q4 (October)
    - Meet with FDA regarding bringing CardioPET P2B into the US (2H '16)

    (Hopefully) coming milestones (unknown timing):
    - Merger/acquisition of Ground Flour Pharma - "coming months" - during CC, they said they likely have a lead investor to consummate the deal
    - Money in the bank through a capital raise (or other) to get the financial overhang out of the way and fund the P3/P3 trials of PFPET and CardioPET through commercialization
    - More licensing agreements - either with the new GFP tech, or licensing out 1 or both of the the homegrown products to other geographical areas.

    If I missed anything, feel free to add.

    We have been waiting for this company to get to the execution phase for a long time now. It looks like we just got there, and added a new technology that can provide some near term (albeit mild) revenue and allow us to make PFPET at a yield and scale that allows the commercialization to move forward and (more importantly) be profitable.

    At the end of the CC, they said they now have enough $$$$ on hand to get the company through the merger and move the development of both CardioPET and BFPET forward as outlined above.

  • That is one hell of an improvement and speaks to the value proposition with the acquisition being acquired. The credentials of the members of GFP are impressive to say the least.

    http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00202?journalCode=acncdm

    [18F]MFBG was prepared in almost 3-fold higher yield than previously reported (31% corrected to end of bombardment, n = 9) in a synthesis time of 56 min with 99.9% radiochemical purity. Other than pH adjustment and dilution of the final product, no reformulation was necessary after purification. This method permits the automated production of multidose batches of clinical grade [18F]MFBG. Moreover, if ongoing clinical imaging trials of [18F]MFBG are successful, this methodology is suitable for rapid commercialization and can be easily adapted for use on most commercial automated radiosynthesis equipment.

PYMXQ
0.000.00(0.00%)Aug 27 2:56 PMEDT